NewAmsterdam Pharma Company N.V. (NasdaqGM: NAMS)
Health Care · Biotechnology · NL
$27.87
+3.30% today · +12.8% 1Y
NewAmsterdam Pharma Company N.V. (NasdaqGM: NAMS) operates in the Biotechnology industry within the Health Care sector. The company is valued at $3.33B and employs 100 people.
Over the last twelve months the share price has gained 12.8%, trading between 23.05 and 42.21.
Tweenvest scores NewAmsterdam Pharma Company N.V. across four factors: quality 40/100, value 50/100. Its strongest factor is value.
NAMS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.33B
- Revenue (TTM)
- $7.12M
- P/E
- —
- EPS
- -2.14
- Dividend yield
- —
- Beta (5Y)
- 0.11
- 52-week high
- $42.21
- 52-week low
- $23.05
- Avg volume (3M)
- —
- Shares outstanding
- 119.54M
- Employees
- 100
- Next earnings
- —
About NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
- Listed since
- Feb 9, 2021
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.